These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 23650027

  • 1. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.
    Affolter K, Samowitz W, Tripp S, Bronner MP.
    Genes Chromosomes Cancer; 2013 Aug; 52(8):748-52. PubMed ID: 23650027
    [Abstract] [Full Text] [Related]

  • 2. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, von Knebel Doeberitz M, Kloor M.
    Int J Cancer; 2013 Oct 01; 133(7):1624-30. PubMed ID: 23553055
    [Abstract] [Full Text] [Related]

  • 3. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H, Galván JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, Economou M, Hammer C, Lugli A, Zlobec I.
    Int J Cancer; 2014 May 15; 134(10):2342-51. PubMed ID: 24166180
    [Abstract] [Full Text] [Related]

  • 4. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
    Estrella JS, Tetzlaff MT, Bassett RL, Patel KP, Williams MD, Curry JL, Rashid A, Hamilton SR, Broaddus RR.
    Mol Cancer Ther; 2015 Dec 15; 14(12):2887-95. PubMed ID: 26438153
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
    Adackapara CA, Sholl LM, Barletta JA, Hornick JL.
    Histopathology; 2013 Aug 15; 63(2):187-93. PubMed ID: 23763264
    [Abstract] [Full Text] [Related]

  • 6. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L, Kuan SF, Dudley B, Brand R, Nikiforova M, Pai RK.
    Am J Surg Pathol; 2016 Oct 15; 40(10):1390-9. PubMed ID: 27438990
    [Abstract] [Full Text] [Related]

  • 7. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
    Kuan SF, Navina S, Cressman KL, Pai RK.
    Hum Pathol; 2014 Mar 15; 45(3):464-72. PubMed ID: 24529329
    [Abstract] [Full Text] [Related]

  • 8. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
    Dvorak K, Higgins A, Palting J, Cohen M, Brunhoeber P.
    Pathol Oncol Res; 2019 Jan 15; 25(1):349-359. PubMed ID: 29127628
    [Abstract] [Full Text] [Related]

  • 9. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis.
    Minoo P, Moyer MP, Jass JR.
    J Pathol; 2007 Jun 15; 212(2):124-33. PubMed ID: 17427169
    [Abstract] [Full Text] [Related]

  • 10. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors.
    Lubomierski N, Plotz G, Wormek M, Engels K, Kriener S, Trojan J, Jungling B, Zeuzem S, Raedle J.
    Cancer; 2005 Sep 01; 104(5):952-61. PubMed ID: 16015629
    [Abstract] [Full Text] [Related]

  • 11. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
    Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A.
    Acta Neuropathol; 2011 Jul 01; 122(1):11-9. PubMed ID: 21638088
    [Abstract] [Full Text] [Related]

  • 12. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
    Bettstetter M, Dechant S, Ruemmele P, Grabowski M, Keller G, Holinski-Feder E, Hartmann A, Hofstaedter F, Dietmaier W.
    Clin Cancer Res; 2007 Jun 01; 13(11):3221-8. PubMed ID: 17545526
    [Abstract] [Full Text] [Related]

  • 13. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
    Ilie MI, Long-Mira E, Hofman V, Mouroux J, Vignaud JM, Gauchotte G, Begueret H, Merlio JP, Emile JF, Hébuterne X, Hofman P.
    Pathology; 2014 Jun 01; 46(4):311-5. PubMed ID: 24798160
    [Abstract] [Full Text] [Related]

  • 14. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
    Bessa X, Ballesté B, Andreu M, Castells A, Bellosillo B, Balaguer F, Castellví-Bel S, Paya A, Jover R, Alenda C, Titó L, Martinez-Villacampa M, Vilella A, Xicola RM, Pons E, Llor X, Gastrointestinal Oncology Group of Spanish Gastroenterological Association.
    Clin Gastroenterol Hepatol; 2008 Feb 01; 6(2):206-14. PubMed ID: 18096441
    [Abstract] [Full Text] [Related]

  • 15. BRAF V600E mutation-specific antibody: A review.
    Ritterhouse LL, Barletta JA.
    Semin Diagn Pathol; 2015 Sep 01; 32(5):400-8. PubMed ID: 25744437
    [Abstract] [Full Text] [Related]

  • 16. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F, Barrantes-Freer A, Skardelly M, Nieser M, Christians A, Stockhammer F, Rohde V, Tatagiba M, Hartmann C, Stadelmann C, Schittenhelm J.
    Diagn Pathol; 2016 Jun 27; 11(1):55. PubMed ID: 27350555
    [Abstract] [Full Text] [Related]

  • 17. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.
    Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B.
    Mol Cancer; 2006 Jan 10; 5():2. PubMed ID: 16403224
    [Abstract] [Full Text] [Related]

  • 18. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
    Lasota J, Kowalik A, Wasag B, Wang ZF, Felisiak-Golabek A, Coates T, Kopczynski J, Gozdz S, Miettinen M.
    Am J Surg Pathol; 2014 Sep 10; 38(9):1235-41. PubMed ID: 24832158
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms.
    Vakiani E, Yaeger R, Brooke S, Zhou Y, Klimstra DS, Shia J.
    Appl Immunohistochem Mol Morphol; 2015 Jul 10; 23(6):438-43. PubMed ID: 25517872
    [Abstract] [Full Text] [Related]

  • 20. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
    Rössle M, Sigg M, Rüschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP.
    Virchows Arch; 2013 Nov 10; 463(5):623-31. PubMed ID: 24085553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.